
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech is well-positioned for long-term success due to multiple factors, including strong clinical data from ongoing trials such as the DURIPANC study in combination with AstraZeneca's Imfinzi, a focus on pancreatic cancer with high market potential, and multiple shots on goal with major cancer research centers. Additionally, the current valuation is attractive, and further positive data from clinical trials could act as a catalyst for the stock. Potential risks include balance sheet and liquidity risks and failure to obtain regulatory approvals or suitable reimbursement.
Bears say
AIM ImmunoTech is focused on the development of Ampligen, a promising double-stranded RNA molecule with potential applications in multiple cancers, viral diseases, and immune-related disorders. The ongoing DURIPANC clinical trial, in collaboration with AstraZeneca and Erasmus MC, holds promising potential for the treatment of metastatic pancreatic cancer. With strong upcoming catalysts expected over the next year, AIM ImmunoTech could see significant growth and success in the near future.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares